BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cyprotex (COTXF.PK): 2009 Interim Results


8/12/2009 10:59:05 AM

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company (“Cyprotex” or “the Company” or “the Group”), today reports its Interim results for the half year to 30 June 2009.

Financial Highlights

• Revenues up 9% to £2.45m (H1 2008: £2.25m)

• Net profit up to £157,000 (H1 2008: profit £56,000)

• Cash and cash equivalents at 30 June £1.72m (H1 2008: £276,000)

• Fully diluted EPS increased to 0.09p (H1 2008: 0.04p)

Operational Highlights

• Expansion of commercial activities

o Continuing to successfully service our largest customer

o Three customers developed to strategic partner level

o Two new Cloe®Select assays launched

o Launch of Cloe®Gateway secure portal

o ‘Pay per use’ access via Cloe®Gateway of Cloe®PKv2.1 and Cloe®HIA predictive software

o Acquisition of an AB Sciex QTRAP®5500 LC-MS/MS mass spectrometer allowing significant expansion of metabolite id offering

o New specialist laboratory fit out and operational

o Targeting new markets: agrichemical, neutraceutical and cosmetic industries

• Key management hires

o John Dootson, Chief Financial Officer

o Simon Bury, Chief Commercial Officer

o European based ADME expert consultant

o New European Business Development Manager

Commenting on the results, Steve Harris, Chairman of Cyprotex PLC, said: “With the new management changes now in place, the Company has performed well in the first half of 2009, consolidating revenue the gains and profitability of 2008. In the face of a challenging market for the CRO industry, our investments in additional products and services are beginning to bear fruit with the generation of significant revenues and new customers and we will continue to drive this momentum forward into 2010.”


Read at BioSpace.com

Cyprotex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES